Skip to main content
. Author manuscript; available in PMC: 2015 Nov 5.
Published in final edited form as: Sci Transl Med. 2014 Nov 5;6(261):261ra152. doi: 10.1126/scitranslmed.3009318

Fig. 1. Eribulin-BFL accumulation phenotype observed in native and taxol-resistant cells.

Fig. 1

(A) Structure of fluorescent eribulin-BFL (green shows BODIPY fluorescent tag). Synthesis is described in fig. S1. (B) The fluorescent eribulin analog, eribulin-BFL, retained an anticancer efficacy in HT1080 cells in vitro, comparable to the unlabeled compound. Data were measured in triplicate at escalating drug concentrations. (C) The fluorescent BODIPY tag did not impede drug uptake in wild type (taxane-sensitive) HT1080 cells in vitro. In contrast, sporadic accumulation of eribulin-BFL was observed in taxol-resistant HT1080 cells. Images were acquired at identical exposure settings.